Johnson & Johnson MedTech CEO Tim Schmid said the company is entering its next phase of growth with a sharper focus on surgical robotics, cardiovascular technologies and targeted portfolio management.

Guidance was raised again, with operational sales growth midpoint moving to 5.1% (previous: 4.8%) and reported sales growth midpoint at 5.7% (previous: 5.4%), reflecting increased confidence in both Innovative Medicine and MedTech.

Q3 2025 Earnings Call Transcript October 14, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.8, expectations were $2.76. Operator: Good morning, and welcome to Johnson & Johnson’s Third Quarter 2025 Earnings Conference Call.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly today on third-quarter results that came in ahead of the consensus forecast.

Get the latest on Johnson & Johnson’s Q3 earnings, MedTech trends, and M&A updates. See why analysts are bullish and what drives JNJ’s outperformance.

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s total revenues.

Johnson & Johnson ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.